As India reels under a second and more deadly wave of the COVID-19 pandemic, the COVID drug FabiFlu sales witness a jump of 600% in the month of April. Glenmark's FabiFlu, the generic version of Japanese anti-influenza drug Favipiravir is now the top-selling brand in the pharma retail market of India, data shows. However, in April, when COVID-19 cases in India first breached four lakh infections a day, the top-selling drugs became Zincovit, Dolo, Monocef and Betadine. Fabiflu mops up Rs 762 cr sales in the last 12 months, higher than the anti-diabetic drug, Glycomet-GP sales of Rs 564 crore. In March, FabiFlu registered sales of Rs 48.3 crore when India was registering around 15,000 cases daily.

Source: dna May 11, 2021 07:18 UTC